Literature DB >> 24833097

Tim-3 expression is increased on peripheral T cells from diffuse large B cell lymphoma.

Taiwu Xiao1, Li Zhang, Lei Chen, Guozhen Liu, Zhenjun Feng, Lei Gao.   

Abstract

T cell immunoglobulin- and mucin-domain-containing molecule 3 (Tim-3) plays a critical role in immune tolerance by suppressing the activation and proliferation of T cells. The purpose of this study was to investigate the effect of Tim-3 on the development of diffuse large B cell lymphoma (DLBCL). A total of 40 newly diagnosed DLBCL patients and 30 healthy donors were recruited. Tim-3 expression on peripheral CD4+ T and CD8+ T cells was analyzed by flow cytometry. Data showed that expression of Tim-3 was significantly increased on both CD4+ and CD8+ T cells in DLBCL patients than in healthy controls (P < 0.001 and P < 0.001, respectively). Also, level of Tim-3 on CD4+ T cells was positively correlated with CD8+ T cells in patients (P < 0.001). Further analyses revealed that patients with advanced tumor stages had elevated Tim-3 expression on CD4+ and CD8+ T cells compared to those with primary tumor stages. In addition, levels of Tim-3 on CD4+ and CD8+ T cells were significantly elevated in DLBCL patients with bone marrow involvement or B symptoms. Our results suggest that Tim-3 is involved in the development of DLBCL.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24833097     DOI: 10.1007/s13277-014-2080-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  24 in total

1.  Expression of TIM-3 on CD4+ and CD8+ T cells in the peripheral blood and synovial fluid of rheumatoid arthritis.

Authors:  Shufeng Li; Dayong Peng; Yeteng He; Hu Zhang; Huaqiang Sun; Shiying Shan; Yuanlin Song; Shuzhen Zhang; Hong Xiao; Haihan Song; Ming Zhang
Journal:  APMIS       Date:  2014-02-23       Impact factor: 3.205

2.  The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway.

Authors:  Rodrigo Liberal; Charlotte R Grant; Beth S Holder; Yun Ma; Giorgina Mieli-Vergani; Diego Vergani; Maria Serena Longhi
Journal:  Hepatology       Date:  2012-07-06       Impact factor: 17.425

Review 3.  Emerging Tim-3 functions in antimicrobial and tumor immunity.

Authors:  Kaori Sakuishi; Pushpa Jayaraman; Samuel M Behar; Ana C Anderson; Vijay K Kuchroo
Journal:  Trends Immunol       Date:  2011-06-21       Impact factor: 16.687

Review 4.  Tim-3, a negative regulator of anti-tumor immunity.

Authors:  Ana Carrizosa Anderson
Journal:  Curr Opin Immunol       Date:  2012-01-04       Impact factor: 7.486

5.  Tim-3 on peripheral CD4⁺ and CD8⁺ T cells is involved in the development of glioma.

Authors:  Song Han; Sizhe Feng; Lunshan Xu; Weiwei Shi; Xuhui Wang; Hao Wang; Chunyong Yu; Tao Dong; Minhui Xu; Guobiao Liang
Journal:  DNA Cell Biol       Date:  2014-02-10       Impact factor: 3.311

Review 6.  Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma.

Authors:  Soham Puvvada; Samantha Kendrick; Lisa Rimsza
Journal:  Cancer Genet       Date:  2013-09-27

7.  BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Authors:  Dennie T Frederick; Adriano Piris; Alexandria P Cogdill; Zachary A Cooper; Cecilia Lezcano; Cristina R Ferrone; Devarati Mitra; Andrea Boni; Lindsay P Newton; Chengwen Liu; Weiyi Peng; Ryan J Sullivan; Donald P Lawrence; F Stephen Hodi; Willem W Overwijk; Gregory Lizée; George F Murphy; Patrick Hwu; Keith T Flaherty; David E Fisher; Jennifer A Wargo
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531

8.  Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC.

Authors:  Xuewei Zhuang; Xiaoning Zhang; Xiyan Xia; Cuijuan Zhang; Xiaohong Liang; Lifen Gao; Xin Zhang; Chunhong Ma
Journal:  Am J Clin Pathol       Date:  2012-06       Impact factor: 2.493

9.  Tim-3 expression on peripheral T cell subsets correlates with disease progression in hepatitis B infection.

Authors:  Wei Wu; Yu Shi; Jie Li; Feng Chen; Zhi Chen; Min Zheng
Journal:  Virol J       Date:  2011-03-11       Impact factor: 4.099

10.  TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.

Authors:  Xin Gao; Yibei Zhu; Gang Li; Haitao Huang; Guangbo Zhang; Fengming Wang; Jing Sun; Qianting Yang; Xueguang Zhang; Binfeng Lu
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

View more
  6 in total

Review 1.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

2.  Single-Cell RNA-Seq and Bulk RNA-Seq Reveal Intratumoral Heterogeneity and Tumor Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.

Authors:  Yang Zhao; Hui Xu; Mingzhi Zhang; Ling Li
Journal:  Front Genet       Date:  2022-05-04       Impact factor: 4.772

3.  Roles of PD-1, Tim-3 and CTLA-4 in immunoregulation in regulatory T cells among patients with sepsis.

Authors:  Dong-Na Gao; Zhi-Xiang Yang; Qing-Hui Qi
Journal:  Int J Clin Exp Med       Date:  2015-10-15

4.  Abnormal expression of Tim-3 antigen on peripheral blood T cells is associated with progressive disease in osteosarcoma patients.

Authors:  Hongliang Liu; Liqiang Zhi; Ning Duan; Pengxiao Su
Journal:  FEBS Open Bio       Date:  2016-07-09       Impact factor: 2.693

5.  Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma.

Authors:  Tingting Zhang; Tianyuan Ren; Zheng Song; Jing Zhao; Lei Jiao; Zhenzhen Zhang; Jin He; Xianming Liu; Lihua Qiu; Lanfang Li; Shiyong Zhou; Bin Meng; Qiongli Zhai; Xiubao Ren; Zhengzi Qian; Xianhuo Wang; Huilai Zhang
Journal:  J Immunol Res       Date:  2020-10-29       Impact factor: 4.818

Review 6.  Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL).

Authors:  Wenqi Zhang; Yanfeng Fan; Meng Li; Linqi Yang; Zhenya Zhang; Lihong Liu
Journal:  Dis Markers       Date:  2021-09-16       Impact factor: 3.434

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.